J.POD Solutions
providing partners with unmatched flexibility to quickly and cost-effectively produce high quality early phase clinical to commercial biologic drug substances
J.POD® biomanufacturing facility in Redmond, WA
- The J.POD facility is an economical, small-footprint, deployable cGMP biomanufacturing plant
- Configured to produce early development to commercial scale quantities of biologic products in support of multi-regional clinical programs and global commercial markets
- Explore our full suite of CDMO services leveraging J.DESIGN
Our biomanufacturing approach
- Process intensification with flexible, continuous processing performed in modular autonomous cleanrooms to reduce overall plant size
- Single use systems and reconfigurable cleanroom pods for maximum flexibility
- J.POD® accommodates perfusion, intensified fedbatch, semicontinuous, and end-to-end continuous biomanufacturing processes at a standard 500L scale to deliver a few kilograms for “first-in human” studies to metric tons of drug substance (commercial biomanufacturing) for large market commercial supply


How early mAb optimization can improve developability and reduce costs
- Most failures during the discovery and early clinical development of mAb-based therapies results from a lack of efficacy and/or safety issues
- Intrinsic molecular properties can result in lead candidates that are difficult to manufacture or keep stable in formulation. This leads to process development and manufacturing challenges that have a significant impact on costs and timelines
- Just-Evotec Biologics uses its Abacus™ software, an in-house suite of proprietary computational tools that enable prediction of the nest molecules and conditions for development
Advancing process design for accessible monoclonal antibody (mAb) based therapeutics
- A common challenge: How to rapidly develop and manufacture lead candidates and obtain approval for an IND or IMPD to progress into clinical trials
- Choosing a cell culture process format is driven by the need for speed, low CoGs, and predictable performance
- Just-Evotec Biologics uses intensified perfusion cell culture processes with significantly increased bioreactor productivity
